Can itraconazole be co‑administered with the standard four‑drug anti‑tuberculosis regimen (isoniazid, rifampin, pyrazinamide, ethambutol)?

Itraconazole Should Not Be Co-administered with Standard Anti-TB Therapy Containing Rifampin

Itraconazole cannot be safely co-administered with rifampin-containing tuberculosis regimens due to a clinically significant drug interaction that leads to suboptimal itraconazole absorption and potential treatment failure of both the fungal infection and tuberculosis. 1

The Critical Drug Interaction

The British Thoracic Society guidelines explicitly warn that rifampin and isoniazid can interact with azole antifungal drugs, and specifically that rifampin can inhibit itraconazole absorption when taken simultaneously, potentially leading to failure of antituberculosis treatment 1. This is a bidirectional problem:

• Rifampin reduces itraconazole levels to subtherapeutic concentrations through enzyme induction
• Inadequate itraconazole levels fail to treat the fungal infection
• The interaction may compromise TB treatment efficacy as well

Management Options

When a patient requires both antifungal therapy and TB treatment, you have three practical approaches:

Option 1: Modify the Antifungal Agent (Preferred)

• Switch to an alternative antifungal that does not interact with rifampin
• Consider amphotericin B formulations or echinocandins depending on the fungal pathogen
• This preserves the optimal rifampin-based TB regimen

Option 2: Modify the TB Regimen (Less Desirable)

• Omit rifampin from the TB regimen and extend treatment duration to 18 months 1
• Use isoniazid, pyrazinamide, and ethambutol (or streptomycin)
• This significantly prolongs TB treatment and reduces efficacy
• Only consider when alternative antifungals are contraindicated or unavailable

Option 3: Substitute Rifabutin for Rifampin

• Rifabutin has less enzyme-inducing activity than rifampin
• May have reduced interaction with itraconazole, though data are limited
• Requires dose adjustments and careful monitoring
• This option is mentioned in guidelines primarily for protease inhibitor interactions 1

Critical Pitfalls to Avoid

Do not assume the interaction is manageable by dose adjustment alone. The enzyme induction by rifampin is profound and cannot be reliably overcome by increasing itraconazole doses. The FDA label for itraconazole does not provide guidance on co-administration with rifampin, which itself signals the problematic nature of this combination 2.

Do not compromise TB treatment quality. Tuberculosis is a life-threatening infection requiring optimal therapy. If itraconazole is essential and no alternatives exist, modifying the TB regimen is justified, but this decision should involve infectious disease consultation.

HIV-Positive Patients

This interaction is particularly relevant in HIV-positive patients who may require both TB treatment and antifungal prophylaxis or treatment. The guidelines note that reactions to antituberculosis drugs are more common in HIV-positive individuals 1, adding another layer of complexity. In these patients, the choice of antifungal agent becomes even more critical to avoid compromising either infection's treatment.

Practical Implementation

1. Before starting TB therapy: Review all concurrent medications, including antifungals
2. If itraconazole is currently prescribed: Switch to a non-interacting antifungal before initiating rifampin
3. If both are already prescribed: Immediately assess therapeutic drug levels if available, and transition to alternative therapy
4. Document the interaction: Ensure all prescribers are aware of this contraindication

The evidence is clear and consistent across multiple guidelines: rifampin and itraconazole should not be used together 1. This is not a relative contraindication requiring monitoring—it is an absolute incompatibility requiring alternative therapeutic strategies.